key: cord-0998147-g12zzwze
authors: Abbattista, Maria; Martinelli, Ida; Peyvandi, Flora
title: Comparison of adverse drug reactions among four COVID‐19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites
date: 2021-08-25
journal: J Thromb Haemost
DOI: 10.1111/jth.15493
sha: f73d52430edc74c7791f673043f544e2e9102631
doc_id: 998147
cord_uid: g12zzwze

BACKGROUND: Real‐world experience with adenoviral vector vaccines against COVID‐19 raised some safety concerns. Cases of cerebral vein thrombosis (CVT) associated with thrombocytopenia have been observed after the first dose of the adenoviral vector vaccines CHADOX1 NCOV‐19 and AD26.COV2.S. OBJECTIVES: To assess the reporting rate of CVT as adverse drug reaction (ADR) for the COVID‐19 vaccines authorized in Europe. PATIENTS AND METHODS: This observational study assessed the CVT reporting rate attributed to four COVID‐19 vaccines authorized in Europe, namely Tozinameran (Pfizer‐Biontech), CX‐024414 (Moderna), CHADOX1 NCOV‐19 (AstraZeneca), and AD26.COV2.S (Janssen). Data on thrombotic ADRs reported on EudraVigilance database between January 1, 2021 and July 30, 2021, were collected. ADRs referring to CVT were identified. The reporting rate of CVT was expressed as 1 million individual vaccinated‐days with 95% confidence interval. Finally, an observed‐to‐expected (OE) analysis was performed. RESULTS: The reporting rate of CVT per 1 million person vaccinated‐days was 1.92 (95% confidence interval [CI], 1.71–2.12) for Tozinameran, 5.63 (95% CI, 4.74–6.64) for CX‐024414, 21.60 (95% CI, 20.16–23.11) for CHADOX1 NCOV‐19, and 11.48 (95% CI, 9.57–13.67) for AD26.COV2.S. CVT occurred alongside thrombocytopenia for the four vaccines. The OE ratio was greater than one for all four vaccines, both with the lowest and the highest CVT background incidence. CONCLUSIONS: This report on EudraVigilance data strengthens anecdotal findings on CVT following COVID‐19 vaccinations. Although the European Medicines Agency released an alert only for CHADOX1 NCOV‐19 and AD26.COV2.S, Tozinameran and CX‐024414 also are complicated by CVT, albeit to lesser extent.

and AD26.COV2.S, 6 with blood clots and thrombocytopenia listed as very rare side effects. The aim of this study was to assess, using the EudraVigilance database, the reporting rate of CVT among the thrombotic adverse drug reactions (ADRs) attributed to the four COVID-19 vaccines authorized by EMA.

The EudraVigilance is a public pharmacovigilance database, available at www.adrre ports.eu, that allows managing and analyzing the ADRs, thus enabling post-marketing surveillance in Europe. We collected ADRs (access date July 30, 2021) for Tozinameran, CX-024414, CHADOX1 NCOV-19, and AD26.COV2.S. Individual case safety reports (ICSRs) submitted from all the European Member States from January 1, 2021 to July 30, 2021 (210 days) were exported to an internal database. ADRs related to thrombotic events were selected from the total using the following filtering conditions:

(1) Reported suspected reaction contains "thrombosis"; (2) Gateway date "01/01/2021--30/07/2021." Cases were reviewed and CVT defined if at least one among "cerebral thrombosis," "cerebral venous/vein thrombosis," "cerebral venous sinus thrombosis," "jugular vein thrombosis," or "sagittal/transverse sinus thrombosis" was present in the reaction list. Splanchnic vein thrombosis (SVT) was attributed if at least one among "splanchnic/splenic vein thrombosis," "portal vein thrombosis," "mesenteric vein thrombosis," or "portosplenomesenteric venous thrombosis" was listed. In addition, multiple unusual sites were determined if CVT, SVT, and/or terms such as "renal/ovarian/retinal/subclavian vein thrombosis" were reported together in the same ICSR. Otherwise, reports containing at least "thrombosis" among suspected reactions were considered as "common sites," either arterial or venous. Thrombocytopenia was declared with "thrombocytopenia," "low platelet count," or "platelet count decreased" listed among suspected reactions.

The reporting rate of CVT during the study period was estimated using the following formula: number of thrombotic ADRs reported in europa.eu/en/publi catio ns-data/data-covid -19-vacci natio n-eu-eea).

Each estimate was expressed as 1 million individual vaccinated-days with the respective 95% confidence interval (CI). An observed-toexpected (OE) analysis within 28 days post first vaccine dose was also performed, considering the estimated lowest CVT background incidence rates and the highest CVT background incidence rates of 0.2 and 1.5 per 100,000 person-years, respectively. The persontime at risk was calculated as number of first doses x 28/365.2425 x 1/100,000. The OE ratio was expressed as standardized morbidity ratio (SMR) with 95% CI.

We identified for each vaccine the total number of ADRs reported in the study period and selected those related to thrombotic events, Table 1 shows the distribution of thrombotic ADRs according to the age group and sex. Overall, the age group <65 was more prevalent among the thrombotic ADRs of adenoviral vector vaccines than among those of mRNA vaccines and the prevalence of female sex was approximately 55% for the four vaccines. CVT events were observed for all vaccines, a lower reporting rate of unusual site thrombosis ADRs was observed for the mRNA compared to the adenoviral vaccines ( Table 2) . CVT events alongside with thrombocytopenia have been reported for all vaccines, ranging from 3-5% to 31-44% for mRNA and adenoviral vaccines, respectively.

• Cases of cerebral vein thrombosis (CVT) occurred mainly after COVID-19 adenoviral vaccines.

• Cases of CVT adverse drug reactions for the four COVID-19 vaccines were retrieved from the EudraVigilance database.

• Cases of CVT did occur with the four vaccines, albeit at different rates.

• Cases of CVT was accompanied by thrombocytopenia for the four vaccines. for CHADOX1 NCOV-19, and 11.48 (95% CI, 9.57-13.67) for AD26.

COV2.S. In Table 3 the OE analysis showed SMR greater than one for all four vaccines, both with the lowest and the highest known background incidence, suggesting an excess of risk. However, when the highest background incidence was considered, the SMR was lower for both the mRNA vaccines than for adenoviral vector ones.

This study employed the EudraVigilance data to evaluate the reporting rate of CVT after COVID-19 vaccination, with the goal to provide a comprehensive look at thrombotic complications with the available vaccines. Rare thromboses at unusual sites, with or without thrombocytopenia, have been reported in EudraVigilance for the four vaccines, even though thrombocytopenia appeared to be more prevalent in patients who developed thrombosis after the adenoviral vector vaccines. Moreover, a higher prevalence of CVT was observed in the <65 years old group for adenoviral vector vaccines than for the others. However, this observation should be interpreted cautiously considering the different target populations who did benefit from each vaccine. Adenoviral vaccines have been mostly used in the young and AD26.COV2.S was only recently introduced, so we cannot exclude that the observed different reporting rates are due to a selection bias. Moreover, the reporting rate of CVT for AD26.

COV2.S was likely to be affected by the low number of individuals who did benefit from this vaccine.

Concerning the extent of the CVT disease burden, CVT incidence increased in the general population over the past decade, from 2-5 to 13.2-15.7 annual cases per million, owing to growing awareness and improved imaging techniques. 7, 8 Yet, these figures are likely to be underestimated because of lack of dedicated epidemiological studies and variability of ethnic groups with different degree of exposure to infectious diseases, well-known triggers of CVT. Moreover, the reporting rate of CVT could not be directly compared to the incidence rate in the general population, these being different measures that use different definitions of the time at risk. Therefore, whether the incidence of CVT is higher in vaccinated people than in the general population is beyond the scope of this study. However, the OE analysis showed an SMR greater than one suggesting an excess of risk for all four vaccines, but particularly for the adenoviral vector ones considering the highest background incidence rate. These data should be critically interpreted because they are based on several assumptions 9 and we do not know the exact background incidence rates, which could widely differ among the vaccine target populations. In addition, a possible underestimation of the ADRs' registration should be considered.

This study has the typical limitations of a study based upon pharmacovigilance data. First, the possibility of underreporting should TA B L E 1 All thrombotic adverse drug reactions stratified by age group and sex Abbreviations: CI, confidence interval; CVT, cerebral vein thrombosis; SMR, standardized morbidity ratio.

Thrombocytopenia and intracranial venous sinus thrombosis after "COVID-19 Vaccine AstraZeneca" exposure

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

The Incidence of Cerebral Venous Thrombosis

Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought

Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines

Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites

to missing information on possible confounders. Moreover, we fail to provide reporting rates standardized for age and countries due to missing data. Considering that the safety profile of a vaccine may differ within each target population (i.e., higher risks in the youngest age groups), comparison between different reporting rates for age categories or countries should be avoided, because they will include many biases and lack of appropriateness. In addition, we lacked information for performing a stratified OE analysis.In conclusion, although EMA released an alert only for adenoviral vector vaccines (CHADOX1 NCOV-19 and AD26.COV2.S), mRNA vaccines (Tozinameran and CX-024414) also are complicated by CVT, albeit to a lesser extent. In accordance with the EMA statements, the benefits of vaccination against COVID-19 continue to outweigh the risks of side effects, including rare life-threatening thrombotic manifestations that appear to occur with all four vaccines but with possible differences in frequency and mechanism that need further investigation. Therefore, we prompt more awareness on the pivotal role of pharmacovigilance, especially for those events that remain unnoticed during the clinical trials and urge spontaneous reports. 

All authors had full access to all study data and take responsibility for their integrity and for the accuracy of the data analysis. M.A. acquired, analyzed, and interpreted the data, and drafted the manuscript. I.M. interpreted the data and critically revised the manuscript. F.P. conceived the study, interpreted the data, and critically revised the manuscript. F.P. and I.M. supervised the study.

https://orcid.org/0000-0003-3620-3347Ida Martinelli https://orcid.org/0000-0001-9218-3622Flora Peyvandi https://orcid.org/0000-0001-7423-9864